Clinical Trials
59 trialsModified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Fudan University
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Tongji Hospital
FUTURE-SUPER
Fudan University
SPARK
Fudan University
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Fudan University
BRPCNCC-1
Changhai Hospital
MARIO-3
Infinity Pharmaceuticals, Inc.
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
Shanghai Zhongshan Hospital
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Hunan Cancer Hospital
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
NeoPATH
Ruijin Hospital
FOOTPATH
Ludwig-Maximilians - University of Munich
HIFU
The First Affiliated Hospital with Nanjing Medical University
Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis:Single-arm, Prospective Clinical Study
Zhongshan Hospital Xiamen University
Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer
Xijing Hospital
NURE-Combo
IRCCS San Raffaele
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
INSIGHT
Fudan University
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
Ruijin Hospital
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Shengjing Hospital
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
The First Hospital of Jilin University
Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Pyramid
Tianjin Medical University Cancer Institute and Hospital
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
Sichuan Cancer Hospital and Research Institute
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Sun Yat-sen University
Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
Huazhong University of Science and Technology
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
Peking Union Medical College Hospital
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
Tianjin Medical University Cancer Institute and Hospital
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
Fudan University
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Nagoya University
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Fudan University
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
Peking Union Medical College Hospital
Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
Peking Union Medical College Hospital
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer
ChineseAMS
Study of NAC of GA Therapy for Patients With BRPC
Wakayama Medical University
Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers
Henan Provincial People's Hospital
HNSCC
ChineseAMS
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC
Fuzhou General Hospital
Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer
Jilin University
FOXAGAST
GERCOR - Multidisciplinary Oncology Cooperative Group
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
ChineseAMS
ASAGPAC
Peking University